全文获取类型
收费全文 | 198篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 23篇 |
临床医学 | 32篇 |
内科学 | 47篇 |
皮肤病学 | 3篇 |
神经病学 | 34篇 |
特种医学 | 4篇 |
外科学 | 21篇 |
综合类 | 7篇 |
预防医学 | 8篇 |
眼科学 | 1篇 |
药学 | 11篇 |
肿瘤学 | 21篇 |
出版年
2021年 | 4篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 4篇 |
2014年 | 3篇 |
2013年 | 4篇 |
2012年 | 13篇 |
2011年 | 8篇 |
2010年 | 5篇 |
2009年 | 4篇 |
2008年 | 11篇 |
2007年 | 8篇 |
2006年 | 15篇 |
2005年 | 15篇 |
2004年 | 9篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 2篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1974年 | 4篇 |
1973年 | 2篇 |
1972年 | 11篇 |
1971年 | 5篇 |
1970年 | 4篇 |
1969年 | 7篇 |
1968年 | 4篇 |
1967年 | 3篇 |
1966年 | 1篇 |
1965年 | 4篇 |
1964年 | 1篇 |
1963年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有217条查询结果,搜索用时 109 毫秒
1.
2.
3.
4.
5.
6.
Pham Daniel Polgar Beata Toth Tunde Jungling Adel Kovacs Norbert Balas Istvan Pal Endre Szabo Dora Fulop Balazs Daniel Reglodi Dora Szanto Zalan Herczeg Robert Gyenesei Attila Tamas Andrea 《Age (Dordrecht, Netherlands)》2022,44(2):785-803
GeroScience - The neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) have been shown in numerous in vitro and in vivo models of Parkinson’s disease (PD)... 相似文献
7.
Swathi Gujral Meryl A. Butters Alexandre Y. Dombrovski Katalin Szanto 《The American journal of geriatric psychiatry》2021,29(7):709-713
ObjectivesThis study examined whether late-onset (versus early-onset) suicidal behavior is associated with worse cognition.MethodsParticipants included 278 adults aged 50+ years (56 nonpsychiatric comparison group; 67 nonsuicidal depressed older adults; 63 depressed suicide ideators; and 44 late-onset (55+ years) and 48 early-onset suicide attempters (<55 years). Using a case-control design, this study examined group differences in global cognition, episodic memory, information processing speed, and executive functioning, assessed using the Repeatable Battery of Neuropsychological Status and the Trail Making Test from the Delis-Kaplan Executive Function System. Linear regression was used for data analyses.ResultsBoth attempter groups displayed worse executive functioning than nonsuicidal depressed older adults. Late-onset attempters additionally displayed poorer global cognition and processing speed than nonsuicidal depressed older adults and poorer memory than early-onset attempters.ConclusionsLate-onset suicidal behavior is associated with worse performance in a broad range of cognitive domains, possibly reflective of a dementia prodrome. 相似文献
8.
G Jancso MT Jaberansari B Gasz Z Szanto B Cserepes E Rth 《Experimental & Clinical Cardiology》2004,9(1):21-25
OBJECTIVES:
To show that angiotensin-converting enzyme (ACE) inhibition potentiates subthreshold ischemic preconditioning (IPC) via the elevation of bradykinin activity, leading to a fully delayed cardioprotective response.METHODS:
On day 1 of the experiment, pigs were subjected to sham (group 1, controls) or IPC protocols. In groups 2 and 3, 4×5 min and 2×2 min of IPC, respectively, were elicited by occluding the left anterior descending coronary artery with percutaneous transluminal coronary angioplasty inflatable balloon catheter. Group 4 was subjected to the ACE inhibitor perindoprilate only. In group 5, the pigs were pretreated with perindoprilate (0.06 mg/kg) and then subjected to 2×2 min IPC. In group 6, intracoronary HOE 140 (a selective bradykinin B2 receptor antagonist) was added before the perindoprilateaugmented subthreshold (2×2 min) PC stimulus. On the second day, all animals underwent 40 min left anterior descending coronary artery ligation and 3 h reperfusion, followed by infarct size analysis using triphenyl tetrazolium chloride staining.RESULTS:
The rates of infarct size and risk zone were the following in the experimental groups: group 1, 42.8%; group 2,19.5% (P<0.05); group 3, ischemia/reperfusion (I/R) 33.4%; group 4, I/R 18.4% (P<0.05); group 5, I/R 31.2%; and group 6, I/R 36.3%. A significant increase of nuclear factor kappa B activation in groups 2 and 4 was seen.CONCLUSIONS:
Results confirm that ACE inhibitors do not give total pharmacological IPC, but they enhance the induction effect of small ischemic insults, which raises the ischemic tolerance of myocardium. It was determined that enhanced bradykinin activity leads to downstream nuclear factor kappa B activation in this model. 相似文献9.
Dougados M Braun J Szanto S Combe B Geher P Leblanc V Logeart I 《Rheumatology (Oxford, England)》2012,51(9):1687-1696
Objective. To evaluate the longer-term efficacy of etanercept in patients with severe and advanced active AS. Methods. Seventy-seven patients who completed the randomized, double-blind, placebo-controlled 12-week SPINE study enrolled in a 12-week open-label extension and received s.c. etanercept 50?mg once weekly. The etanercept/etanercept group received a total of 24 weeks treatment with etanercept (n?=?38); the placebo/etanercept group received placebo during the double-blind study then 12 weeks' etanercept treatment during the open-label extension (n?=?39). Results. At the end of the open-label extension, BASDAI scores in the etanercept/etanercept group had further decreased beyond reductions observed during the double-blind study [mean (s.d.) change from baseline -37.6 (22.4) at end of extension vs -27.4 (23.8) at end of double-blind study]. Mean (s.d.) BASDAI scores also improved in the placebo/etanercept group once switched to etanercept [-28.6 (24.3) vs -15.0 (20.0)]. Similar trends were observed in BASFI and BASMI scores. In the placebo/etanercept group, total back pain decreased to similar levels achieved in the etanercept group in the double-blind study. Pain levels continued to decrease with longer-term etanercept therapy in the etanercept/etanercept group. Conclusion. Despite the improvements in symptoms and inflammatory markers observed shortly after initiation of once-weekly etanercept, there was no notable plateauing effect on patient-reported outcomes. Indeed, signs and symptoms of severe and advanced active AS continued to improve after up to 24 weeks, treatment with etanercept. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/home, NCT00420238. 相似文献
10.